Al Roker, Type 2 Diabetes, and Insulin: Press Coverage and Public Statements

What Al Roker Has Said Publicly About His Type 2 Diabetes

Al Roker has been one of the most candid American media personalities about living with Type 2 diabetes. His disclosures span more than 20 years of interviews, memoir writing, and social media posts, making his case a documented public record rather than speculation.

Roker discussed his diabetes diagnosis in connection with his 2002 gastric bypass surgery. In the years following that surgery, he described substantial improvements in his blood glucose control. He has also acknowledged, in later interviews, that weight regain complicated his ongoing diabetes management and that medication, including insulin at certain periods, became part of his treatment plan.

The 2002 Gastric Bypass and Its Metabolic Effects

Roker underwent Roux-en-Y gastric bypass surgery in November 2002 at Lenox Hill Hospital in New York City. He weighed approximately 340 lbs at the time of surgery.

Bariatric surgery produces rapid improvements in glycemic control that often precede significant weight loss. A landmark meta-analysis published in The Lancet (Buchwald et al., 2009, N=135,246 patients) found that 78.1% of patients with Type 2 diabetes experienced complete remission after bariatric surgery, with Roux-en-Y gastric bypass producing the highest rates [1]. The mechanism involves changes in gut hormone secretion, particularly GLP-1 and GIP, which improve beta-cell function and insulin sensitivity independent of caloric restriction.

Roker lost more than 100 lbs after surgery and reported dramatic changes in his health markers. He described the experience in his 2012 book Never Goin' Back: Winning the Weight Loss Battle for Good, where he addressed both the physical transformation and the psychological dimensions of living with obesity and diabetes.

Weight Regain and the Return of Diabetes Challenges

Roker has been equally open about weight regain. By the early 2020s, he had regained a significant portion of the weight he had initially lost, acknowledging this publicly on the Today show and in interviews. Weight regain after bariatric surgery is well-documented. A 2020 study in JAMA Surgery found that patients regained a mean of 30% of their maximum lost weight within 10 years of Roux-en-Y gastric bypass [2].

Weight regain directly correlates with the return or worsening of Type 2 diabetes. When fat mass increases again, particularly visceral adipose tissue, insulin resistance climbs. Beta cells that had been able to compensate post-surgically may struggle again as metabolic demand increases.

Roker has not specified exact HbA1c values in public statements, which is appropriate. What he has confirmed is that his diabetes management has required active medical intervention at multiple points over the past two decades.

Al Roker's Statements on Insulin Use

Roker has acknowledged using insulin as part of his Type 2 diabetes treatment. He discussed this in the context of explaining why bariatric surgery and later weight management efforts were medically necessary rather than cosmetic decisions.

What He Has Said on Record

In various Today show segments and print interviews, Roker framed his diabetes management in terms of what was required to stay healthy enough to work and remain present for his family. He has described insulin as one of the tools his medical team used during periods when oral medications were insufficient to maintain glycemic control.

It is worth being precise here: Roker has not published a detailed medication list or shared specific insulin regimens publicly. What he has confirmed, on multiple occasions, is that his diabetes required pharmaceutical intervention beyond lifestyle changes alone, and that insulin was part of that picture at certain times. Any characterization beyond this documented record would be inference, and we label it as such.

The clinical framework here is standard for long-duration Type 2 diabetes with a history of significant obesity. The American Diabetes Association's 2024 Standards of Care in Diabetes states: "For patients with Type 2 diabetes who do not achieve or maintain glycemic targets with noninsulin therapies, insulin therapy should be initiated without delay" [3]. Patients with a history of bariatric surgery who later regain weight often cycle through this clinical scenario, as the metabolic benefits of surgery are not permanent if weight is regained substantially.

The GLP-1 Question: What Medications Might Fit His Profile

Roker has not publicly confirmed using a GLP-1 receptor agonist such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). However, given his documented history of Type 2 diabetes, weight regain, and prior bariatric surgery, the clinical profile would fit the labeled indications for these agents.

The ADA 2024 guidelines recommend GLP-1 receptor agonists as preferred add-on therapy for patients with Type 2 diabetes who have established cardiovascular disease, high cardiovascular risk, or who need additional weight management [3]. The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg or 1 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26% versus placebo (HR 0.74, 95% CI 0.58.0.95, P<0.001 for noninferiority) [4].

We do not assert that Roker takes any GLP-1 agent. This section provides clinical context for readers who encounter speculation about his medication regimen online.

Clinical Context: Type 2 Diabetes After Bariatric Surgery

Understanding Roker's health journey requires understanding what bariatric surgery does, and does not do, for Type 2 diabetes over a 20-year horizon.

Short-Term Remission Is Common

The evidence for short-term remission is strong. The STAMPEDE trial, published in The New England Journal of Medicine (Schauer et al., 2017, N=150), found that at 5 years, 29% of patients in the gastric bypass arm had achieved HbA1c <6.0% without diabetes medications, compared with 5% in the intensive medical therapy arm [5]. This is genuine remission by most definitions.

Roker's early post-surgical years appear consistent with this pattern. He described substantially improved health in the years immediately following his 2002 procedure.

Long-Term Durability Is Not Guaranteed

The picture at 10 to 20 years is more complicated. A 2018 study in Diabetes Care following patients for a median of 12 years after Roux-en-Y gastric bypass found that diabetes remission rates dropped from 72% at 2 years to 47% at 10 years [6]. Relapse was strongly associated with weight regain, longer pre-surgical diabetes duration, and baseline insulin use.

Roker's history of weight regain and his acknowledgment of ongoing medical management fit this pattern precisely. His case is not unusual in the bariatric literature. It is, however, unusually visible given his platform.

Insulin in Long-Duration Type 2 Diabetes

Type 2 diabetes is a progressive condition. The United Kingdom Prospective Diabetes Study (UKPDS), which followed patients for up to 20 years, demonstrated that beta-cell function declines at roughly 4% to 5% per year regardless of initial treatment [7]. Over a 20-plus year diabetes history, the probability of eventually requiring insulin is high for most patients.

The ADA 2024 guidelines note that basal insulin (such as insulin glargine or insulin degludec) is the preferred starting insulin for most patients with Type 2 diabetes, typically dosed at 10 units per day or 0.1 to 0.2 units per kg per day, titrated to fasting glucose targets of 80 to 130 mg/dL [3]. Intensification to basal-bolus regimens or premixed insulins occurs when HbA1c remains above target despite optimized basal dosing.

The Role of Public Disclosure in Diabetes Awareness

Roker's openness about his diabetes diagnosis and treatment has clinical value beyond his personal narrative. Public figures who discuss chronic disease management can shift patient behavior measurably.

What the Research Says About Celebrity Health Disclosure

A 2017 analysis in The BMJ examined the "Angelina Jolie effect" on BRCA testing rates and found that high-profile disclosures can produce population-level changes in health-seeking behavior [8]. The mechanism is not complicated: people see a trusted public figure discussing a condition and become more willing to speak to their own physicians about similar symptoms or risks.

Roker's repeated discussion of Type 2 diabetes, insulin use, and bariatric surgery over more than two decades represents a sustained example of this phenomenon in metabolic disease. Diabetes affects an estimated 38.4 million Americans, or 11.6% of the US population, according to the CDC's 2023 National Diabetes Statistics Report [9]. Of those, approximately 8.5 million are estimated to be undiagnosed.

When a recognizable face on morning television discusses managing blood sugar and taking insulin, it reduces the stigma that prevents some patients from seeking care or disclosing their condition to their employers, families, or physicians.

Bariatric Surgery Awareness

Roker's 2002 surgery preceded the current era of widespread public discussion about metabolic surgery. His willingness to discuss it openly, including complications he experienced publicly after the procedure, contributed to broader awareness that bariatric surgery is a medical intervention, not a shortcut.

The American Society for Metabolic and Bariatric Surgery notes that fewer than 1% of eligible patients in the United States undergo bariatric surgery annually, despite strong evidence for its effectiveness in treating obesity and Type 2 diabetes. Visibility from public figures discussing their experiences may play some role in reducing barriers to consideration.

2022 Health Crisis and Recovery: What Roker Disclosed

In November 2022, Roker was hospitalized for blood clots, including a pulmonary embolism. He spent 28 days in the hospital during November and December 2022 and later described the experience as life-threatening. He disclosed these details publicly on the Today show in January 2023 upon his return.

The clinical connection to diabetes is indirect but relevant. Type 2 diabetes is an independent risk factor for venous thromboembolism. A 2020 meta-analysis in Diabetes Care (N=1,942,730 participants across 16 cohort studies) found that individuals with diabetes had a 23% higher risk of venous thromboembolism compared with those without diabetes (relative risk 1.23, 95% CI 1.10.1.37) [10].

Roker did not attribute his pulmonary embolism to diabetes in his public statements, and we do not assert that connection here. The data simply contextualizes why physicians managing patients with long-duration Type 2 diabetes maintain vigilance for thromboembolic risk alongside glycemic control.

His recovery was prolonged. He missed the Macy's Thanksgiving Day Parade for the first time in 27 years. He returned to the Today show on January 6, 2023.

Second Bariatric Procedure in 2023

In 2023, Roker underwent a second weight-loss procedure. He discussed this publicly, framing it as a medically necessary step given the weight regain he had experienced. He did not disclose the specific type of procedure in detail in the interviews reviewed for this article.

Revisional bariatric surgery is a growing area of metabolic medicine. A 2021 review in Surgery for Obesity and Related Diseases found that revision procedures performed for weight regain or inadequate initial loss can produce additional mean excess weight loss of 40% to 60%, with corresponding improvements in diabetes control [11].

Whether Roker's 2023 procedure resulted in changes to his insulin regimen or other diabetes medications has not been publicly confirmed. Clinically, weight loss of 10% to 15% body weight in patients with Type 2 diabetes can reduce HbA1c by 1.0 to 2.0 percentage points, often allowing medication reduction or discontinuation in patients with shorter diabetes duration.

Summary of Documented Statements Versus Inference

Readers deserve clarity about what is confirmed versus what is clinical context.

Confirmed by Roker's public statements:

• Type 2 diabetes diagnosis, discussed publicly in connection with his 2002 surgery
• Roux-en-Y gastric bypass surgery, November 2002, Lenox Hill Hospital
• Initial weight of approximately 340 lbs, with subsequent loss of over 100 lbs
• Weight regain over the subsequent two decades
• Insulin use as part of his diabetes management at unspecified periods
• Hospitalization in November to December 2022 for blood clots and pulmonary embolism
• A second weight-loss procedure in 2023

Clinical inference, labeled as such:

• The specific insulin products, doses, or regimens he has used are not publicly known
• Whether he uses or has used GLP-1 receptor agonists is not confirmed
• Current HbA1c or fasting glucose values are not in the public record
• The type of his 2023 revisional procedure has not been definitively disclosed in reviewed sources

This distinction matters. Readers searching for information about their own diabetes management should consult a board-certified endocrinologist or primary care physician, not derive treatment assumptions from a celebrity's health narrative.